Implantica Achieves Major Public Tender Wins in Italy
Implantica AG (publ.) has made significant strides in the medical technology sector with recent public tender victories, securing more than €1.2 million in funding for its revolutionary RefluxStop® device designed for acid reflux treatment. This innovative device targets the treatment of gastroesophageal reflux disease (GERD), a condition affecting approximately one billion people globally.
Details of the Funding and Its Significance
The public tenders were awarded to Implantica at two key healthcare institutions in Italy, namely the Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" in Palermo and the Ospedale di Brunico under the Azienda Sanitaria dell'Alto Adige in South Tyrol. These approvals reflect the growing acceptance of RefluxStop® within Italy's national healthcare framework, paving the way for its wider adoption and ongoing reimbursement processes throughout Europe.
Impact on Patient Care
The clinical benefits of RefluxStop® are already being realized in various hospitals across Italy. Currently, there are 12 RefluxStop® Centers of Excellence established, providing specialized services to GERD patients. Prof. Antonino Agrusa, an Associate Professor of Surgery at the University of Palermo and the leading surgeon at the Policlinico "Paolo Giaccone," noted, "Our patients show remarkable improvement nearly a year following the procedure, experiencing no reflux and enhanced swallowing functionality. This represents a transformative shift for many patients in Sicily."
Perspectives from Medical Leaders
Dr. Günther Sitzmann, who oversees the General Surgery Department at Ospedale di Brunico, emphasized the device's role in restoring patients' quality of life. He stated, "With RefluxStop®, our patients can engage in activities that were once hampered by GERD. It is incredibly fulfilling to provide relief to those who had resigned themselves to living with discomfort."
The Vision Behind RefluxStop®
Dr. Peter Forsell, CEO of Implantica and the innovator behind RefluxStop®, articulated the importance of governmental acknowledgment for the device's efficiency and its far-reaching impact on patient outcomes. He expressed heartfelt gratitude toward Prof. Agrusa and Dr. Sitzmann for their unwavering dedication to improving GERD patient access to effective treatments. The securing of these public tenders is a pivotal milestone towards broader acceptance and long-term reimbursement of the device, further enhancing Implantica's mission to revolutionize GERD treatments for over 12 million adults in Italy and one billion people globally.
Implantica continues to lead the charge in establishing advanced technologies in patient care, promoting solutions that enhance the quality of life for individuals suffering from GERD. The company is committed to delivering innovative healthcare solutions, and the recent funding success positions it for a bright future.
Frequently Asked Questions
What is RefluxStop®?
RefluxStop® is an innovative device developed by Implantica for the treatment of gastroesophageal reflux disease (GERD), aiming to improve patient outcomes significantly.
How much funding has Implantica secured?
Implantica has secured over €1.2 million in public healthcare funding through recent tender approvals in Italy.
What institutions are involved in the public tenders?
The public tenders were awarded to the Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" in Palermo and the Ospedale di Brunico in South Tyrol.
What is the significance of these tender approvals?
These approvals signify a major step forward for the acceptance and integration of RefluxStop® within Italy's healthcare system, promoting wider usage and reimbursement capabilities.
Who can benefit from RefluxStop®?
Individuals suffering from GERD can benefit from RefluxStop®, particularly those seeking relief from the debilitating effects of acid reflux.
